IMUNON to Participate in the H.C. Wainwright Global Investment Conference
2023年9月5日 - 9:30PM
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology
company, announces that management will participate in the H.C.
Wainwright 25th Annual Global Investment Conference being held
September 11-13, 2023. A webcast of the IMUNON presentation will be
available on the Events section of the Company’s website beginning
Monday, September 11 at 7:00 a.m. Eastern time.
Management is available throughout the
conference for virtual one-on-one meetings. Institutional investors
and industry professionals can register to attend the conference
virtually or in-person at the Lotte New York Palace Hotel.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies.
IMUNON has two platform technologies: the
TheraPlas modality for the development of immunotherapies and other
anti-cancer nucleic acid-based therapies, and the PlaCCine modality
for the development of nucleic acid vaccines for infectious
diseases and cancer. The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting preclinical proof-of-concept studies on a nucleic acid
vaccine candidate (IMNN-101) targeting the SARS-CoV-2 virus to
validate its PlaCCine platform. IMUNON’s platform technologies are
based on the delivery of nucleic acids with novel synthetic
delivery systems that are independent of viral vectors or devices.
IMUNON will continue to leverage these platforms and to advance the
technological frontier of nucleic acid-based products to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024